Lord Freyberg: To ask His Majesty's Government how much the National Gallery raised in image fees from their image licensing department in 2021–22 and 2022–23; and what costs that were directly applicable to the sale of image licenses were incurred.
Lord Freyberg: To ask His Majesty's Government what assessment they have made of (1) the amount that local councils spend to fund (a) leisure centres, and (b) swimming pools, and (2) the extent to which this varies across England.
Lord Freyberg: To ask His Majesty's Government, further to the Written Answers by Lord Parkinson of Whitley Bay on 1 December (HL3495 and HL3496), what is Art Council England's national opera strategy; and whether they will put on hold their plans to withdraw all national programme funding from English National Opera until one has been published.
Lord Freyberg: My Lords, as the last speaker before the Front-Bench speakers, I will focus my remarks, as others have today, on opera, and in particular the ENO following the Arts Council’s recent decision to withdraw all national programme funding from this organisation. Like the noble Lord, Lord Vaizey, I am concerned that Arts Council England, by its own admission, has made no strategic nationwide...
Lord Freyberg: To ask His Majesty's Government with whom Arts Council England consulted prior to their decision to withdraw all national programme funding from English National Opera.
Lord Freyberg: To ask His Majesty's Government whether Arts Council England discussed with English National Opera a plan of transition from their base in London, prior to their decision to withdraw all national programme funding from the organisation.
Lord Freyberg: To ask His Majesty's Government whether the London Coliseum is under public (1) ownership, or (2) control; and if so, (a) what is its legal status, and (b) whether Arts Council England or any other public body retain any residual control or ownership rights, including the power to sell the venue.
Lord Freyberg: My Lords, as I rise to speak to Motion D1 in the name of the noble Baroness, Lady Thornton, the House will recall I have spoken at length in recent weeks about my support for Amendment 4 and, in particular, the protections it would afford publicly funded data processing services and IT systems in connection with the provision of health and care. The Minister has mentioned in his replies, and...
Lord Freyberg: My Lords, I was privileged to speak at some length about the provisions of this Bill in Grand Committee, and I thank those who supported the amendments in my name, which concerned the role of cutting-edge, data-driven medical devices. The Minister has since reassured me of his intention to further explore their implications in the course of a consultation exercise about their definition and...
Lord Freyberg: My Lords, I am delighted to follow the noble Baroness, Lady Thornton, and congratulate her on her excellent and persuasive speech. I am pleased to contribute to consideration on Report of the Trade Bill and to speak to the new Amendment 11. There is some question as to the status of new and enhanced digital trade provisions in replacement deals, such as the CEPA signed by the UK and Japan in...
Lord Freyberg: My Lords, I thank the Minister for his helpful reply. I will take him up on his offer to facilitate further discussions on the Medicines and Medical Devices Bill. I take the point that the Government prize the privacy, safety and security of citizens above all else, including their data rights, and have not and would never relinquish control of policy-making or regulation in respect of the...
Lord Freyberg: My Lords, I thank the noble Lord, Lord Grimstone, for the opportunity to speak today about trade agreements involving healthcare data and technology and, in moving Amendment 71, I shall speak also to Amendment 72 in this group. Noble Lords will be aware that I am a long-standing advocate for the use of patient data to provide better healthcare, and some will know that my motivation is...
Lord Freyberg: My Lords, I add my congratulations to the two maiden speakers. I have spoken before about the need to better harness the value of healthcare data in the UK. Today I want to draw attention to the need for clear provisions on data trade in the Bill, where they could usefully assuage concerns about privacy and patient safety, as well as help guarantee that economic benefits flow from the next...
Lord Freyberg: My Lords, I have spoken at length about the value of harnessing healthcare data in the UK, and the Bill reads across to that topic. The Bill is needed to regulate medicines and the estimated 500,000 medical devices licensed for manufacture world- wide as we transition from membership of the European Union. However, it is heavily reliant on definitions set out in the Medical Devices...
Lord Freyberg: To ask Her Majesty's Government how many COVID-19 tests have been made available but not processed as part of the NHS Test and Trace programme, broken down by the local authority area (1) to which they were sent, or (2) in which they were administered.
Lord Freyberg: To ask Her Majesty's Government what has been the total cost of COVID-19 tests which have been made available but not processed since 1 January.
Lord Freyberg: To ask Her Majesty's Government how many COVID-19 tests have been made available but not processed; and of those, how many relate to each pillar of the NHS Test and Trace programme.
Lord Freyberg: To ask Her Majesty's Government what plans they have to consult key stakeholders and external experts on future Data Protection Impact Assessments for the management, storage and handling of NHS controlled data.
Lord Freyberg: To ask Her Majesty's Government what plans they have to carry out a Data Protection Impact Assessment on the rights and freedoms of the people whose health data is collected by the NHS; and whether any such data is protected against access by intelligence services.
Lord Freyberg: To ask Her Majesty's Government what plans they have to competitively tender for future technology products and services that were commissioned during the first stage of the COVID-19 pandemic.
